Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-069 vs Nplate in Idiopathic Thrombocytopenic Purpura
NCT05220878Phase 3Completed
- Sponsor
- Generium
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of GNR-069 in immune thrombocytopenia (ITP) (2 arms), sponsored by Generium. Primary endpoint: Proportion of patients achieving sustained response to treatment at 26 weeks. Started Sep 2021; status: completed.
02
Drugs
GNR-069
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05220878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05220878.